UNITAID Approves $160M For Investments In Hepatitis C, TB, Malaria

UNITAID has committed $160 million in new grants for investments in hepatitis C, drug-resistant tuberculosis, and malaria chemoprevention. According to a press release, “These innovative investments will reduce prices, overcome market barriers to access for patients, and generate crucial data on new products to speed up their introduction for those most in need.” Grants approved by UNITAID’s executive board this week include grants to Médecins Sans Frontières, Partners in Health, the Malaria Consortium, and Northwestern Global Health Foundation (5/6).